Free Trial

Paragon 28 (FNA) Stock Forecast & Price Target

$8.53
+0.43 (+5.31%)
(As of 07/23/2024 ET)

Paragon 28 - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 5 Wall Street analysts who have issued ratings for Paragon 28 in the last 12 months, the stock has a consensus rating of "Buy." Out of the 5 analysts, 5 have given a buy rating for FNA.

Consensus Price Target

$16.75
96.37% Upside
High Forecast$20.00
Average Forecast$16.75
Low Forecast$14.00

According to the 5 analysts' twelve-month price targets for Paragon 28, the average price target is $16.75. The highest price target for FNA is $20.00, while the lowest price target for FNA is $14.00. The average price target represents a forecasted upside of 96.37% from the current price of $8.53.

TypeCurrent Forecast
7/25/23 to 7/24/24
1 Month Ago
6/25/23 to 6/24/24
3 Months Ago
4/26/23 to 4/25/24
1 Year Ago
7/25/22 to 7/25/23
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$16.75$16.75$17.67$27.67
Forecasted Upside96.37% Upside80.16% Upside69.60% Upside49.65% Upside
Get Paragon 28 Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for FNA and its competitors with MarketBeat's FREE daily newsletter.

FNA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

FNA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Paragon 28 Stock vs. The Competition

TypeParagon 28Medical CompaniesS&P 500
Consensus Rating Score
3.00
2.72
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside96.37% Upside2,973.35% Upside9.72% Upside
News Sentiment RatingNeutral News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/9/2024JMP Securities
2 of 5 stars
 Lower TargetMarket Outperform ➝ Market Outperform$23.00 ➝ $20.00+144.20%
5/9/2024Piper Sandler
2 of 5 stars
 Reiterated RatingOverweight ➝ Overweight$18.00 ➝ $15.00+57.89%
5/9/2024Needham & Company LLC
3 of 5 stars
 Lower TargetBuy ➝ Buy$17.00 ➝ $14.00+47.37%
4/5/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$18.00+80.00%
9/29/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
B. Vazquez
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
12/14/2022B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
N. Chatterji
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$32.00+57.17%
8/5/2022Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Kyle Rose
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Target$20.00 ➝ $25.00+26.90%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 04:38 AM ET.

FNA Forecast - Frequently Asked Questions

What is Paragon 28's forecast for 2024?

According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Paragon 28 is $16.75, with a high forecast of $20.00 and a low forecast of $14.00.

Should I buy or sell Paragon 28 stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Paragon 28 in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FNA shares.

Does Paragon 28's stock price have much upside?

According to analysts, Paragon 28's stock has a predicted upside of 80.16% based on their 12-month stock forecasts.

What analysts cover Paragon 28?

Paragon 28 has been rated by research analysts at JMP Securities, Needham & Company LLC, and Piper Sandler in the past 90 days.

Do Wall Street analysts like Paragon 28 more than its competitors?

Analysts like Paragon 28 more than other "medical" companies. The consensus rating for Paragon 28 is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how FNA compares to other companies.


This page (NYSE:FNA) was last updated on 7/24/2024 by MarketBeat.com Staff

From Our Partners